The 4E-BP1/eIF4E ratio is a determinant for rapamycin response in esophageal cancer cells
Authors:
- 1 January 2015
- journal article
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 149 (1) , 378-385
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinomaCancer Medicine, 2013
- The matricellular protein CCN1 suppresses lung cancer cell growth by inducing senescence via the p53/p21 pathwayJournal of Cellular Biochemistry, 2013
- Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinomaBritish Journal of Cancer, 2012
- The mTOR Signalling Pathway in Human CancerInternational Journal of Molecular Sciences, 2012
- Sensitivity of Global Translation to mTOR Inhibition in REN Cells Depends on the Equilibrium between eIF4E and 4E-BP1PLOS ONE, 2011
- High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1Cell Cycle, 2011
- 4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in TumorsCancer Cell, 2010
- Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid TumorsJapanese Journal of Clinical Oncology, 2009
- Epigenetic Activation of a Subset of mRNAs by eIF4E Explains Its Effects on Cell ProliferationPLOS ONE, 2007
- Predicted mechanisms of resistance to mTOR inhibitorsBritish Journal of Cancer, 2006